Prosecution Insights
Last updated: October 04, 2026
Application No. 18/845,166

PIPERIDINONE DERIVATIVE OR SALT THEREOF, HARMFUL ORGANISM CONTROL AGENT CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME

Non-Final OA §101§112
Filed
Sep 09, 2024
Priority
Mar 09, 2022 — JP 2022-036205 +1 more
Examiner
MARTIN, KEVIN STEPHEN
Art Unit
Tech Center
Assignee
Nihon Nohyaku Co., Ltd.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
1y 4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
122 granted / 158 resolved
+17.2% vs TC avg
Strong +23% interview lift
Without
With
+23.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
184
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
24.3%
-15.7% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
41.5%
+1.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 158 resolved cases

Office Action

§101 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims The amendments to the claims filed September 9, 2024 are acknowledged and entered. Claims 1-11 are pending. Priority This application is a 371 of PCT/JP2023/008567, filed March 7, 2023, which claims priority of JP 2022-036205, filed March 9, 2022. Information Disclosure Statement Acknowledgement is made of the Information Disclosure Statement filed on December 13, 2024. All references have been considered except where marked with a strikethrough. Specification The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any of the errors of which applicant may become aware of in the specification. Election/Restriction The requirement for restriction mailed July 7, 2026 has been reconsidered and is hereby withdrawn. The full scope of claims 1-11 are presently under examination. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 11 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim does not fall within at least one of the four categories of patent eligible subject matter because the claims are drawn to a “use” and not to a patentable process, machine, manufacture, or composition of matter. The claim appears to claim a process; however, does not recite any steps involved in the process. “’Use’ claims that do not purport to claim a process, machine, manufacture, or composition of matter fail to comply with 35 U.S.C. 101.” See MPEP 2173.05(q). Claim Rejections - 35 USC § 112b The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 11 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 11 is drawn to a “use” of the claimed compound. The claim appears to claim a process; however, does not recite any steps involved in the process. “Attempts to claim a process without setting forth any steps involved in the process generally raises an issue of indefiniteness under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph.” See MPEP 2173.05(q). Allowable Subject Matter Claims 1-10 are allowed. The following is an examiner’s statement of reasons for allowance: The closest references to the instant claims are Graham et al. (WO2017/102649)(hereinafter “Graham”) and Yip (Diss. Abstr. Int., B 2007, Abstract)(hereinafter “Yip”). Yip (see Abstract) and Graham (see Examples beginning at page 113) teach the compounds which are excluded from the instant claims (see claim 1, “provided…structural formulas are excluded). There is no teaching or suggestion provided in either reference which would have motivated a person of ordinary skill in the art before the effective filing date of the instant application to selectively modify these compounds into the claimed invention with any reasonable expectation of success. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. September 16, 2026 /K.S.M./Examiner, Art Unit 1624 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Sep 09, 2024
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746239
COMPOSITIONS AND METHODS COMPRISING ENDOTHELIN A RECEPTOR ANTAGONISTS AND ANDROGEN THERAPIES
4y 10m to grant Granted Sep 29, 2026
Patent 12747214
IMIDAZOLE-BASED SYNTHETIC LIPIDOIDS FOR IN VIVO MRNA DELIVERY INTO IMMUNE CELLS
4y 0m to grant Granted Sep 29, 2026
Patent 12746241
SOLID PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 11m to grant Granted Sep 29, 2026
Patent 12746222
IMPLANTABLE DEPOTS FOR LOCALIZED, SUSTAINED, CONTROLLED RELEASE OF THERAPEUTIC AGENTS TO TREAT CANCER AND RELATED CONDITIONS
3y 5m to grant Granted Sep 29, 2026
Patent 12740981
COMPOSITIONS AND METHODS FOR TREATING CANCER
4y 9m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+23.2%)
3y 5m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 158 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month